Fatigue SymptomSUJOK-COPDNCT07746596
Su Jok for Dyspnea and Fatigue
A study testing Su Jok Therapy in people with Fatigue Symptom and Chronic Obstructive Lung Disease, run by Erzincan Binali Yildirim Universitesi at 1 site in Turkey (Türkiye).
Trial summary
As the disease progresses, dyspnea and fatigue may increasingly interfere with daily activities, reduce patients' independence, and negatively affect their quality of life. Therefore, in addition to pharmacological treatment, there is a need for safe and supportive interventions to help alleviate these symptoms. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fatigue Symptom, Chronic Obstructive Lung Disease, Dyspnea
- What is being tested?
- Su Jok Therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 Jan 2026to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older.
- Diagnosed with chronic obstructive pulmonary disease (COPD).
- Able to communicate verbally.
- Expected to remain hospitalized for at least 5 days to ensure completion of the intervention.
- No major health condition other than COPD that could adversely affect activities of daily living (e.g., open wounds, cancer, or gastrointestinal disorders).
- Provided written informed consent to participate in the study.
- A Visual Analog Scale (VAS) score of 3 or higher for dyspnea and fatigue.
Who cannot join
- Declined or were unable to provide written informed consent.
- Unable to communicate verbally.
- Conditions preventing the application of Su Jok therapy to the hands, including neuropathy, amputation, open wounds, or other hand disorders.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of Su Jok Therapy on Dyspnea and Fatigue in Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
As the disease progresses, dyspnea and fatigue may increasingly interfere with daily activities, reduce patients' independence, and negatively affect their quality of life. Therefore, in addition to pharmacological treatment, there is a need for safe and supportive interventions to help alleviate these symptoms. This study aims to evaluate the effects of Su Jok therapy on dyspnea and fatigue in patients with chronic obstructive pulmonary disease (COPD). The findings are expected to provide evidence regarding the potential role of Su Jok therapy as a complementary intervention for symptom management. The results may contribute to improving patients' symptom control and quality of life while providing healthcare professionals with evidence to support clinical decision-making and nursing care.
Read the detailed description
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease characterized by persistent airflow limitation and symptoms such as dyspnea and fatigue, which substantially impair patients' functional capacity and quality of life. Although pharmacological treatment is the cornerstone of COPD management, complementary non-pharmacological interventions may provide additional benefits in symptom control.
Su Jok therapy is a complementary therapy based on the stimulation of corresponding points on the hands and feet. It has been proposed as a simple, non-invasive, and low-cost intervention that may help reduce symptom severity and improve patient well-being. However, evidence regarding its effectiveness in patients with COPD is limited.
This study is designed as a randomized controlled trial to evaluate the effects of Su Jok therapy on dyspnea and fatigue in patients with COPD. Eligible participants will be randomly assigned to either an intervention group receiving Su Jok therapy in addition to routine care or a control group receiving routine care alone. Dyspnea and fatigue will be assessed using validated measurement instruments before and after the intervention. The primary objective is to determine whether Su Jok therapy provides additional benefits in reducing dyspnea and fatigue compared with routine care alone. The findings are expected to contribute to the evidence base regarding complementary therapies in COPD management and to support evidence-based nursing practice.
- Conditions
- Fatigue Symptom, Chronic Obstructive Lung Disease, Dyspnea
- Being tested
- Su Jok Therapy
- Keywords
- dyspnea, Fatigue symptom, Chronic Obstructive Lung Disease, sujok
- Medical subject headings
- Fatigue, Pulmonary Disease, Chronic Obstructive, Dyspnea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Su Jok TherapyOther
Su Jok therapy was administered by the researcher once daily for five consecutive days in addition to routine COPD care. The intervention involved stimulation of predefined Su Jok correspondence points on the hands according to the study protocol. Each session was performed using standardized procedures to ensure consistency throughout the study.
| Study group | Role | What they receive |
|---|---|---|
| Su Jok Therapy Group | Experimental | Participants in this group will receive routine COPD care plus five consecutive daily sessions of Su Jok therapy. Dyspnea and fatigue symptoms will be assessed daily using the Visual Analog Scale (VAS). Questionnaire data will be collected before the intervention (baseline) and after completion of the intervention (post-test). Receives: Other: Su Jok Therapy |
| Control Group | No intervention | Participants in this group will receive routine COPD care only. Dyspnea and fatigue symptoms will be assessed daily for five consecutive days using the Visual Analog Scale (VAS). Questionnaire data will be collected at baseline and after the study period (post-test). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dyspnea
Dyspnea severity will be assessed using the Visual Analog Scale (VAS). Higher scores indicate greater dyspnea severity.
Measured: Baseline and daily for 5 consecutive days, with post-intervention assessment on Day 5.
Secondary outcomes (1)
fatigue severity
fatigue severity will be assessed using the Visual Analog Scale (VAS) and the fatıgue Severity Index (ISI). Higher scores indicate greater fatıgue severity.
Measured: Baseline and post-intervention (Day 5).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2026
- Study start2 Jan 2026
- Primary completion31 Jul 2026
- Study completion1 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fatigue SymptomStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Erzincan Binali Yildirim Universitesi
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sebahat ATALIKOĞLU BAŞKAN, Erzincan Binali Yildirim Universitesi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07746596
- Sponsor's protocol ID
- 2025-664
- Acronym
- SUJOK-COPD
- Status last verified
- Aug 2026
- First submitted
- 31 Jul 2026
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because participant confidentiality and privacy will be protected in accordance with the informed consent and ethics committee approval.
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Su Jok Therapy on Dyspnea and Fatigue in Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07746596
- Acronym / sponsor ID
- SUJOK-COPD / 2025-664
- Conditions
- Fatigue Symptom, Chronic Obstructive Lung Disease, Dyspnea
- Keywords
- dyspnea, Fatigue symptom, Chronic Obstructive Lung Disease, sujok
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Erzincan Binali Yildirim UniversitesiUniversity, hospital or other
- Study start
- 2 Jan 2026 (actual)
- Primary completion
- 31 Jul 2026 (actual)
- Study completion
- 1 Aug 2026 (actual)
- First posted
- 5 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
As the disease progresses, dyspnea and fatigue may increasingly interfere with daily activities, reduce patients' independence, and negatively affect their quality of life. Therefore, in addition to pharmacological treatment, there is a need for safe and supportive interventions to help alleviate these symptoms. This study aims to evaluate the effects of Su Jok therapy on dyspnea and fatigue in patients with chronic obstructive pulmonary disease (COPD). The findings are expected to provide evidence regarding the potential role of Su Jok therapy as a complementary intervention for symptom management. The results may contribute to improving patients' symptom control and quality of life while providing healthcare professionals with evidence to support clinical decision-making and nursing care.
Detailed description
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease characterized by persistent airflow limitation and symptoms such as dyspnea and fatigue, which substantially impair patients' functional capacity and quality of life. Although pharmacological treatment is the cornerstone of COPD management, complementary non-pharmacological interventions may provide additional benefits in symptom control.
Su Jok therapy is a complementary therapy based on the stimulation of corresponding points on the hands and feet. It has been proposed as a simple, non-invasive, and low-cost intervention that may help reduce symptom severity and improve patient well-being. However, evidence regarding its effectiveness in patients with COPD is limited.
This study is designed as a randomized controlled trial to evaluate the effects of Su Jok therapy on dyspnea and fatigue in patients with COPD. Eligible participants will be randomly assigned to either an intervention group receiving Su Jok therapy in addition to routine care or a control group receiving routine care alone. Dyspnea and fatigue will be assessed using validated measurement instruments before and after the intervention. The primary objective is to determine whether Su Jok therapy provides additional benefits in reducing dyspnea and fatigue compared with routine care alone. The findings are expected to contribute to the evidence base regarding complementary therapies in COPD management and to support evidence-based nursing practice.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Su Jok Therapy Group | Experimental | Other: Su Jok TherapyParticipants in this group will receive routine COPD care plus five consecutive daily sessions of Su Jok therapy. Dyspnea and fatigue symptoms will be assessed daily using the Visual Analog Scale (VAS). Questionnaire data will be collected before the intervention (baseline) and after completion of the intervention (post-test). |
| Control Group | No intervention | –Participants in this group will receive routine COPD care only. Dyspnea and fatigue symptoms will be assessed daily for five consecutive days using the Visual Analog Scale (VAS). Questionnaire data will be collected at baseline and after the study period (post-test). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults aged 18 years or older.
- Diagnosed with chronic obstructive pulmonary disease (COPD).
- Able to communicate verbally.
- Expected to remain hospitalized for at least 5 days to ensure completion of the intervention.
- No major health condition other than COPD that could adversely affect activities of daily living (e.g., open wounds, cancer, or gastrointestinal disorders).
Key exclusion criteria (3 listed)
- Declined or were unable to provide written informed consent.
- Unable to communicate verbally.
- Conditions preventing the application of Su Jok therapy to the hands, including neuropathy, amputation, open wounds, or other hand disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Su Jok TherapySu Jok therapy was administered by the researcher once daily for five consecutive days in addition to routine COPD care. The intervention involved stimulation of predefined Su Jok correspondence points on the hands according to the study protocol. Each session was performed using standardized procedures to ensure consistency throughout the study. | Other | Su Jok Therapy Group |
Primary outcome
Dyspnea
Time frame: Baseline and daily for 5 consecutive days, with post-intervention assessment on Day 5.
Dyspnea severity will be assessed using the Visual Analog Scale (VAS). Higher scores indicate greater dyspnea severity.
1 secondary outcome
fatigue severity
Time frame: Baseline and post-intervention (Day 5).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because participant confidentiality and privacy will be protected in accordance with the informed consent and ethics committee approval.
Related trials for Fatigue Symptom
Active, not recruitingPhase 2/3
Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer
Prostate Carcinoma
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Not yet recruiting
COG+OT Telerehabilitation for Adults With Subjective Cognitive Complaints
Subjective Cognitive Complaints, Ehlers-Danlos Syndrome
RecruitingPhase 2
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
Estrogen Receptor-Positive Breast Carcinoma
Not yet recruiting
Impact of Nurse-Led Pulmonary Rehabilitation on Dyspnea, Fatigue and Self-Efficacy in COPD Patients
Chronic Obstructive Pulmonary Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Su Jok Therapy in people with Fatigue Symptom and Chronic Obstructive Lung Disease, run by Erzincan Binali Yildirim Universitesi at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dyspnea (time frame: Baseline and daily for 5 consecutive days, with post-intervention assessment on Day 5.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.